Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

by @JTC_PALIdev | Dec 3, 2024 | Press Releases

First three Single Ascending Dose cohorts demonstrated no treatment related adverse events Carlsbad, CA, Dec. 03, 2024 — Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage...

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn’s Disease and Ulcerative Colitis (UC)

by @JTC_PALIdev | Nov 21, 2024 | Press Releases

Data to be presented at the 8th Annual Antifibrotic Drug Development (AFDD) Summit PALI-2108 may offer a solution for fibrostenotic Crohn’s disease by enhancing efficacy, safety, and therapeutic potential compared to traditional treatments Carlsbad, CA, Nov. 21,...

Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit

by @JTC_PALIdev | Nov 14, 2024 | Press Releases

Presentation to highlight advances in fibrostenotic Crohn’s Disease and the potential of localized PDE4 inhibition Carlsbad, CA, Nov. 14, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the...

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

by @JTC_PALIdev | Nov 12, 2024 | Press Releases

Commenced enrollment and dosing in Phase 1 clinical study of PALI-2108 for the treatment of moderate-to-severe Ulcerative Colitis (UC) Carlsbad, CA, Nov. 12, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the...

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)

by @JTC_PALIdev | Nov 7, 2024 | Press Releases

Carlsbad, CA, Nov. 07, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with...

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

by @JTC_PALIdev | Oct 31, 2024 | Press Releases

Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease (IBD) PALI-2108 demonstrates in ex vivo studies; targeted activation and reduced side effects, potentially enhancing patient compliance compared to existing PDE4 inhibitors...